Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

TenNor Therapeutics (丹诺医药) IPO: Rich Valuation for an Antibacterial Deal

TenNor Therapeutics (丹诺医药) IPO Trading

TeNor Therapeutics (丹诺医药) Pre-IPO Quick Comment: Strong Innovation Constrained by Commercial Outlook

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

TenNor Therapeutics (Suzhou) Limited / Equity Capital Markets

TenNor Therapeutics (Suzhou) Limited (TEN123 HK)

<ul>
<li>TenNor Terapeutics, a China-based clinical-stage biotech company, is looking to raise at least USD 100m via a Hong Kong listing. CITIC and ABCI are the joint book runners.</li>
<li>In our past note, we looked at the company’s core products, rifasutenizol, rifaquizinone, and TNP-2092, as well as the company’s investors backing and management.</li>
<li>In this note, we look at the changes in its latest prospectus, and our updated thoughts on the deal.</li>
</ul>


TenNor Terapeutics, a China-based clinical-stage biotech company, is looking to raise at least USD 100m via a Hong Kong listing. CITIC and ABCI are the joint book runners.
In our past note, we looked at the company’s core products, rifasutenizol, rifaquizinone, and TNP-2092, as well as the company’s investors backing and management.
In this note, we look at the changes in its latest prospectus, and our updated thoughts on the deal.


TenNor Therapeutics (丹诺医药) Pre-IPO: AP Updates and Further Research